By Delilah Alvarado
Published July 17, 2026
In a high-stakes maneuver designed to stave off insolvency and revitalize a depleted clinical pipeline, Jasper Therapeutics has officially completed an all-stock acquisition of the privately held biotech firm Kira Pharmaceuticals. The deal, announced Thursday, arrives as a critical inflection point for Jasper, which had seen its market valuation plummet following a series of clinical setbacks and a desperate pivot toward "strategic alternatives" just one month ago.
To bolster the merger, Jasper simultaneously secured $132 million in a private stock offering. This infusion of capital provides the company with a significant runway, extending its operational capacity through the second half of 2028. While the combined entity will retain the Jasper Therapeutics name and stock ticker, the integration of Kira’s assets marks a fundamental shift in the company’s scientific focus, moving away from its singular reliance on the beleaguered drug candidate briquilimab and toward a more diversified portfolio of immune-system modulators.
The Path to Crisis: A Chronology of Stumbles
Jasper Therapeutics entered the public markets with significant promise, pinning its future on briquilimab—a monoclonal antibody developed to treat chronic spontaneous urticaria (CSU), or severe chronic hives. However, the company’s trajectory hit a severe obstacle in 2025.
2025: The Year of Setbacks
The crisis began in July 2025, when Jasper reported that a "faulty batch" of briquilimab had compromised the data integrity of a pivotal clinical study. The manufacturing error introduced significant noise into the results, rendering the trial’s efficacy data inconclusive and triggering a sharp sell-off in Jasper’s stock.
The fallout was immediate and severe. Recognizing that its cash reserves were rapidly depleting, leadership initiated a radical corporate restructuring. This included:
- Workforce Reduction: A 50% layoff of the total staff to reduce "burn rate."
- Program Termination: The suspension of several early-stage research projects to preserve remaining capital.
- Leadership Turnover: The departure of the Chief Medical Officer, signaling a loss of confidence from the investor community.
2026: The Search for Alternatives
By the first quarter of 2026, the company’s financial position had reached a nadir, with only $14 million in cash remaining as of March 31. Recognizing the lack of a viable independent path forward, the board of directors formally engaged in a process to explore "strategic alternatives"—industry shorthand for seeking a buyer or a transformative merger. This search led the company directly to the doors of Kira Pharmaceuticals.
Kira Pharmaceuticals: A Complement-Focused Powerhouse
Kira Pharmaceuticals, founded in 2020 and backed by prominent venture capital heavyweights including Foresite Capital, RA Capital Management, and Vivo Capital, entered the merger with a robust focus on the "complement system."
The complement system is a sophisticated part of the immune system that serves as a first-line defense against pathogens. However, when dysregulated, this system can contribute to chronic inflammation and tissue damage. Kira’s platform has focused on modulating this system with high precision.
Key Pipeline Assets
The acquisition brings two primary assets into the Jasper fold:
- KP-104: A bifunctional molecule designed to target the complement pathway. It is currently being investigated for paroxysmal nocturnal hemoglobinuria (PNH)—a rare, life-threatening blood disease—as well as severe kidney conditions such as IgA nephropathy (IgAN).
- KP-701: A bispecific drug engineered to suppress B-cell function, offering a dual-action approach to dampening autoimmune responses.
Jasper has committed to accelerating these programs. The company intends to initiate discussions with regulatory authorities regarding a Phase 3 study for KP-701 in PNH, while concurrently preparing to release Phase 2 data for kidney indications in 2027.
Competitive Analysis and Market Implications
The integration of KP-104 is viewed by analysts as the "crown jewel" of the deal. At the recent American Society of Hematology (ASH) meeting, Kira presented Phase 2 data for KP-104 that caught the attention of market watchers.
William Blair analyst Matt Phipps noted that while the initial trial size was modest, the data suggested that KP-104 could possess "best-in-class" potential. Phipps suggested that the drug might even exceed the benchmarks set by Novartis’ blockbuster therapy, Fabhalta. "The clinical profile of KP-104, particularly in its ability to modulate the complement system while maintaining a favorable safety profile, positions it as a potential disruptor in the rare disease space," Phipps wrote in a recent investor note.
The Role of Mirador Therapeutics
As part of the complex financial maneuvering surrounding the merger, Kira concurrently licensed two additional programs to Mirador Therapeutics. Mirador, a startup founded by the former leadership of Prometheus Biosciences—which was sold to Merck in a multi-billion dollar deal—is rapidly building a "precision immunology" portfolio.
The licensing deal involves KP-301, a long-acting antibody targeting the C5 protein, and a companion small-molecule inhibitor. Kira will receive $12 million in upfront cash, with additional milestone payments contingent on development success. This deal serves as a strategic divestiture, allowing the new Jasper to focus its capital and resources on its lead assets (KP-104 and KP-701) while offloading non-core programs to a specialized partner.
Future Outlook: Rebuilding Credibility
The merger has successfully provided Jasper with the oxygen it needed to survive, but the path to long-term valuation recovery remains paved with challenges. The company is not abandoning its roots entirely; it continues to test briquilimab for severe combined immunodeficiency (SCID), a rare and deadly condition. Jasper confirmed it is preparing for a pre-approval submission meeting with the FDA to discuss the potential path forward for this specific indication, which had been previously deprioritized during the 2025 restructuring.
For investors, the success of the new Jasper will depend on three critical factors:
- Execution on the Complement Assets: The transition of KP-104 from Phase 2 into late-stage trials must be seamless to maintain the "best-in-class" narrative established by Kira.
- Regulatory Navigation: With the FDA’s increased scrutiny on autoimmune and blood disorder therapies, the company’s ability to communicate the clinical benefits of its new portfolio will be paramount.
- Financial Discipline: The $132 million raise buys time, but in the volatile biotech sector, the company must demonstrate that it can reach value-creating milestones—such as positive late-stage clinical data—before that runway expires in 2028.
"The merger with Kira is a total reset," says one industry observer familiar with the deal. "Jasper went from a company on the brink of liquidation to one with a legitimate, high-value pipeline. The market is rightfully cautious, but the underlying science of the complement system assets is fundamentally stronger than what Jasper was working with two years ago."
As the integration progresses, the biotech industry will be watching to see if this marriage of convenience can evolve into a clinical success story. For Jasper Therapeutics, the stakes could not be higher: this is, in every sense, their final opportunity to prove they can deliver meaningful therapies to patients and returns to shareholders.
Disclaimer: This article is for informational purposes and does not constitute financial advice. Readers are encouraged to conduct their own due diligence regarding biopharmaceutical investments.
